Ventyx Biosciences Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ventyx Biosciences Inc 's ROA in the third quarter of 2025?
Ventyx Biosciences Inc recorded a cumulative net loss of $-107 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -41.83%.

However, within the Healthcare sector 535 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 3956, from total ROA ranking in the second quarter of 2025 at 4016.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-27.85 %	-23.75 %	-21.67 %	16.85 %	-8.89 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-107	-119	-124	-135	-153
Return On Assets (TTM)	-41.83 %	-43.24 %	-42.29 %	-43.49 %	-51.01 %
VTYX's Total Ranking	# 3956	# 4016	# 4062	# 4727	# 4250
Total Assets (TTM) in million	211	230	253	324	293
Seq. Total Assets Change	-8.06 %	-9.26 %	-21.88 %	10.7 %	-2.84 %
Seq. Net Income Change	-	-	-	-	-

VTYX's 5 Years Annual ROA >> Back to VTYX Management Effectiveness >> Compare VTYX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 226
Sector	# 536
Overall	# 3911

Return On Assets Statistics
High	Average	Low
-17.44 %	-43.24 %	-60.18 %
(Jun 30 2022)		(Mar 31 2024)

News about Ventyx Biosciences Inc Return on Assets ROA

Ventyx Biosciences, a biotechnology company focused on developing innovative therapeutics, has ...

Title : Ventyx Biosciences Advances Parkinson s Research with Phase 2a Trial of VTX3232:Ventyx Biosciences, a biotechnology company focused on developing innovative therapeutics, has officially announced the initiation of dosing in a Phase 2a clinical trial for its investigational drug, VTX3232. The trial aims to evaluate the safety, efficacy, and tolerability of VTX3232 in patients diagnosed with early-stage Parkinson s disease.Parkinson s disease is a progressive neurodegenerative disorder that primarily affects motor function, leading to symptoms such as tremors, rigidity, and balance issues. Current treatment options mainly focus on alleviating symptoms rather than altering disease progression, which underscores the urgent need for new therapeutic candidates.

Financial Statements
Ventyx Biosciences Inc 's Assets	$ 211 million	VTYX's Balance sheet
Ventyx Biosciences Inc 's Income	$ -23 million	Quarterly VTYX's Income Statement
VTYX's Income by Division		See VTYX's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY
Y / Y Total Assets Change	-3.4 %	-25.17 %	27.4 %	-	-
Total Assets in million	268	278	371	291	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-135	-193	-108	-84	0
Annual Return On Assets	-50.37 %	-69.49 %	-29.22 %	-28.75 %	-

VTYX's 5 Years Annual ROA >> Back to VTYX Management Effectiveness >> Compare VTYX ROA to its Competitors

More Return On Assets Ratios
VTYX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VTYX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VTYX's Competitors
Subscribers only: Roa for Ventyx Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for VTYX's Customers

You may also want to know
VTYX's Roi	VTYX's Inventory Turnover Ratio	VTYX's Growth Rates	VTYX's Dividend Comparisons
	VTYX's Profitability Ratios	VTYX's Asset Turnover Ratio	VTYX's Dividend Growth
VTYX's Roe	VTYX's Valuation Ratios	VTYX's Financial Strength Ratios	VTYX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:46:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.